Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders

On June 9, 2026, Apogee Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). As of the close of business on April 15, 2026, the record date for the Annual Meeting, there were 61,853,254 shares of voting common stock entitled to vote at the meeting. The proposals considered at the Annual Meeting are described in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 24, 2026 (the "Proxy Statement"). The final voting results are set forth below.

Proposal 1: Election of Directors

The following Class III director nominees were elected to serve until the 2029 Annual Meeting of Stockholders based upon the following votes:

Proposal 2: Ratification of Independent Auditor Appointment

The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 was ratified as follows:

Proposal 3: Approval on a Non-Binding, Advisory Basis of the Compensation of our Named Executive Officers

The compensation of our named executive officers as disclosed in the Proxy Statement was approved on a non-binding, advisory basis as follows: